Memorial Healthcare System

Influence of Variant of Uncertain Significance (VUS) Genetic Testing Results on Mastectomy Choice in Lumpectomy-Eligible Patients

Abstract Purpose Our objective was to evaluate whether having a germline variant of uncertain significance (VUS) influenced the decision to undergo bilateral mastectomy (BLMast) among lumpectomy-eligible patients with unilateral breast cancer. Methods This retrospective cohort st...

Biliary Duct Invasion in Colorectal Liver Metastases: Prevalence and Clinicopathologic Correlation in a Retrospective Cohort Study

Biliary duct invasion (BDI) is an underrecognized growth pattern of colorectal cancer (CRC) liver metastases that can mimic intrahepatic cholangiocarcinoma or intraductal papillary neoplasm of the bile duct. Its prevalence and clinicopathologic associations remain unclear. This s...

Outcomes of CHOP versus CHOEP/EPOCH in aggressive adult T-cell leukemia/lymphoma: an international cohort analysis

Aggressive adult T-cell leukemia/lymphoma (ATL) subtypes (i.e., acute and lymphomatous) are rare diseases, and the conventional management with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has historically yielded poor outcomes. The benefit of etoposide-conta...

Laparoscopic Cholecystectomy Is a Time-Sensitive Operation: National Outcomes Associated With Delayed Surgery

Background Competition for urgent and emergent operating-room access is a significant challenge in many hospitals. Evidence-based benchmarks for early intervention are well established for emergencies like acute appendicitis or hip fracture. In contrast, laparoscopic cholecystect...

Longitudinal shifts in diabetes care delivery during the COVID-19 pandemic: implications for post-pandemic models of chronic disease management

Abstract Background The COVID-19 pandemic profoundly disrupted chronic disease management, including diabetes care. While early studies described short-term changes in access to care and laboratory monitoring, the long-term evolution of diabetes care delivery remains poorly under...

Efficacy of rituximab plus lenalidomide regimens in follicular lymphoma: a meta-analysis of randomized controlled trials

Follicular lymphoma (FL) is an incurable, indolent non-Hodgkin lymphoma with a high relapse rate despite effective chemoimmunotherapy. Lenalidomide, an immunomodulatory agent, in combination with rituximab (R²), has been evaluated as an alternative to chemoimmunotherapy and to ot...